[HTML][HTML] Oral squamous cell carcinomas: state of the field and emerging directions
Oral squamous cell carcinoma (OSCC) develops on the mucosal epithelium of the oral
cavity. It accounts for approximately 90% of oral malignancies and impairs appearance …
cavity. It accounts for approximately 90% of oral malignancies and impairs appearance …
[HTML][HTML] Clinical update on head and neck cancer: molecular biology and ongoing challenges
Head and neck squamous cell carcinomas (HNSCCs) are an aggressive, genetically
complex and difficult to treat group of cancers. In lieu of truly effective targeted therapies …
complex and difficult to treat group of cancers. In lieu of truly effective targeted therapies …
[HTML][HTML] Therapeutic approaches for the treatment of head and neck squamous cell carcinoma–An update on clinical trials
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common non-skin
cancer with a tobacco consumption and infection with high-risk human papillomavirus (HPV) …
cancer with a tobacco consumption and infection with high-risk human papillomavirus (HPV) …
[HTML][HTML] Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4
Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer
worldwide. Tobacco use is the main risk factor for HNSCC, and tobacco-associated …
worldwide. Tobacco use is the main risk factor for HNSCC, and tobacco-associated …
[HTML][HTML] Controlled drug delivery systems for oral cancer treatment—current status and future perspectives
Oral squamous cell carcinoma (OSCC), which encompasses the oral cavity-derived
malignancies, is a devastating disease causing substantial morbidity and mortality in both …
malignancies, is a devastating disease causing substantial morbidity and mortality in both …
Head and neck cancer: Current challenges and future perspectives
GR Bhat, RG Hyole, J Li - Advances in Cancer Research, 2021 - Elsevier
Head and neck cancers are a heterogeneous, aggressive and genetically complex
collection of malignancies of the oral cavity, nasopharynx, oropharynx, hypopharynx, larynx …
collection of malignancies of the oral cavity, nasopharynx, oropharynx, hypopharynx, larynx …
[HTML][HTML] EPHB2 carried on small extracellular vesicles induces tumor angiogenesis via activation of ephrin reverse signaling
S Sato, S Vasaikar, A Eskaros, Y Kim, JS Lewis… - JCI insight, 2019 - ncbi.nlm.nih.gov
Angiogenesis is a key process that allows nutrient uptake and cellular trafficking and is
coopted in cancer to enable tumor growth and metastasis. Recently, extracellular vesicles …
coopted in cancer to enable tumor growth and metastasis. Recently, extracellular vesicles …
[HTML][HTML] Overcoming resistance to combination radiation-immunotherapy: a focus on contributing pathways within the tumor microenvironment
Radiation therapy has been used for many years to treat tumors based on its DNA-damage-
mediated ability to kill cells. More recently, RT has been shown to exert beneficial …
mediated ability to kill cells. More recently, RT has been shown to exert beneficial …
[HTML][HTML] Anti-EGFR therapies in nasopharyngeal carcinoma
X Chen, R Liang, X Zhu - Biomedicine & Pharmacotherapy, 2020 - Elsevier
Nasopharyngeal carcinoma (NPC) is a common malignant tumor in Southern China and
South-East Asia. Regardless of initiative high response to radiotherapy, parts of patients still …
South-East Asia. Regardless of initiative high response to radiotherapy, parts of patients still …
[HTML][HTML] Oral squamous cell carcinoma cells with acquired resistance to erlotinib are sensitive to anti-cancer effect of quercetin via pyruvate kinase M2 (PKM2)
CY Chan, SC Hong, CM Chang, YH Chen, PC Liao… - Cells, 2023 - mdpi.com
Oral squamous cell carcinoma (OSCC) frequently carries high epidermal growth factor
receptor (EGFR) expression. Erlotinib, a small molecule tyrosine kinase inhibitor (TKI), is an …
receptor (EGFR) expression. Erlotinib, a small molecule tyrosine kinase inhibitor (TKI), is an …